Mexican College for Pharmacoeconomics and … College for Pharmacoeconomics and Outcomes Research,...

ISPOR 2nd LatIn ameRIca cOnfeRence

10-12 SePtembeR 2009SheRatOn RIO hOteL RIO de JaneIRO, bRazIL

InternatIonal SocIety for PharmacoeconomIcS and outcomeS reSearch

Organized by: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the ISPOR Latin america consortium, in coordination with the ISPOR brazil chapter

Program & Schedule of events

Conference Co-Sponsored by: DECIT-CGATS – Department of Science & Technology, Health Technology Assessment General Coordination, Brazilian Ministry of Health, Brazil

São Paulo Center for Health Economics – Federal University of São Paulo, São Paulo, Brazil

IECS – Institute for Clinical Effectiveness & Health Policy, Argentina

Central University of Venezuela, Venezuela

Ministry of Public Health of Ecuador, Ecuador

Simon Bolivar University, Venezuela

The Children’s Hospital of Mexico “Federico Gómez”, Mexico

Mexican College for Pharmacoeconomics and Outcomes Research, Mexico

www.iSpor.org

“Uniting ReseaRch and Policy to imPRove health caRe in latin ameRica”

ISPOR 2nd Latin america conference10-12 SePtembeR 2009 / SheRatOn RIO hOteL / RIO de JaneIRO, bRazIL

Letter from the ISPOR President 38

Letter from the ISPOR 2nd Latin America Conference Program Planning Committee Co-Chairs 39

Conference Program Committee 40

Key Information 40

Conference at-a-glance 42

Conference Short Course Program 43

Program & Schedule of Events 45

Issue Panel Descriptions 54

Workshop Descriptions 58

Sponsored Symposia Descriptions 65

Invited Speaker Biographical Information 70

Research Poster Listing 84

Research Poster Abstracts 95

Research Podium Abstracts 131

ISPOR 2nd Latin America Conference Review Committee Members 142

Exhibit Program 144

Corporate & Event Supporters 146

Conference Room Floor Plan 149

Carta del Presidente de ISPOR 22

Carta de los Co-Presidentes del Comité de Planificación del Programa de la 2da Conferencia ISPOR para América Latina 23

Comité del Programa de la Conferencia 24

Información Clave 24

La Conferencia a grandes rasgos 26

Programa de Cursos Cortos 27

Programa y Agenda de Eventos 29

Descripciones de las Mesas Redondas 54

Descripciones de los Talleres 58

Descripciones de los Simposios Patrocinados 65

Biografías de los Presentadores Invitados 70

Listado de los Afiches de Investigación 84

Resúmenes los Afiches de Investigación 95

Resúmenes de Presentaciones de Investigación en Podio 131

Miembros del Comité de Revisión de la 2da Conferencia ISPOR para América Latina 142

Programa de la Exposición 144

Patrocinadores Corporativos y de Eventos 146

Plano de Salones de la Conferencia 149

PORtuguÊS eSPanÕL engLISh

“Unindo Pesquisa e Política para Melhorar os Cuidados à Saúde na América Latina”“Uniendo la Investigación y Política para Mejorar el Cuidado de la Salud en América Latina”

“Uniting Research and Policy to Improve Health Care in Latin America”

3

Carta do Presidente da ISPOR 6

Carta dos Co-Presidentes do Comitê de Planejamento de Programa da 2ª Conferência ISPOR para a América Latina 7

Comitê do Programa da Conferência 8

Informações Gerais 8

A Conferência em Resumo 10

Programa de Cursos de Curta Duração da Conferência 11

Programa e Calendário de Eventos 13

Descrições dos Painéis de Questões 54

Descrições dos Workshops 58

Descrições dos Simpósios Patrocinados 65

Informação Biográfica dos Palestrantes Convidados 70

Listagem de Pôsteres de Pesquisa 84

Resumos dos Pôsteres de Pesquisa 95

Resumos das Pesquisas em Pódio 131

Membros do Comitê de Revisão da 2ª Conferência ISPOR para a América Latina 142

Programa de Exposição 144

Patrocinadores Corporativos e do Evento 146

Planta das Salas da Conferência 149


Letter from the ISPOR President

Letter from the ISPOR 2nd Latin America Conference Program Planning Committee Co-Chairs

Conference Program Committee

Key Information

Conference at-a-glance

Conference Short Course Program

Program & Schedule of Events

ENGLISH

37

3100 Princeton Pike Building 3, Suite E Lawrenceville, NJ 08648 USAToll Free US and Canada: 1-800-992-0643 Tel: +1 609-219-0773 Fax: +1 609-219-0774Email: [email protected] Internet: www.ispor.org

2009-2010 Board of directorsPresident michael Barry Phd, md National Centre for Pharmacoeconomics St. James’s Hospital Dublin, Ireland [email protected]

President-elect Scott ramsey md, Phd Fred Hutchinson Cancer Research Center University of Washington Seattle, WA, USA [email protected]

Past President chris l. Pashos Phd HERQuLES, Abt Bio-Pharma Solutions, Inc. Lexington, MA, USA [email protected]

directors ansgar hebborn Phd F. Hoffmann-La Roche Basel, Switzerland [email protected]

Shanlian hu md, mSc Fudan University, School of Public Health Shanghai, P.R. China [email protected]

don husereau mSc Canadian Agency for Drugs & Technologies Ottawa, ON, Canada [email protected]

Zeba Khan rPh, Phd Celgene Corporation Summit, NJ, USA [email protected]

Paul Kind Centre for Health Economics University of York Heslington, York, UK [email protected]

Penny mohr ma Center for Medical Technology Policy Baltimore, MD, USA [email protected]

Shelby reed Phd, rPh Duke Clinical Research Institute Duke University Durham, NC, USA [email protected]

treasurer Karen rascati rPh, Phd University of Texas, College of Pharmacy Austin, TX, USA [email protected]

founding executive director marilyn dix Smith rPh, Phd ISPOR Lawrenceville, NJ, USA [email protected]

ISPORUniting Research & Practice

International Society for Pharmacoeconomics and outcomes research

Dear Colleagues,

I am delighted to welcome you to the ISPOR 2nd Latin America Conference in Rio de Janeiro, Brazil. I wish to thank the Conference Planning Committee including the conference Co-Chairs Marcos Bosi Ferraz MD, PhD and Gabriela Tannus Araújo MBA, MSc, in addition to the ISPOR staff, for compiling a very exciting programme. We are very fortunate to be meeting in a city that the the “cariocas” (locals) refer to as “a cidade maravilhosa” or “the wonderful city”, and I am sure you will enjoy your visit.

This ISPOR 2nd Latin America Conference affords another opportunity for us to move towards the ISPOR Vision 2010 of a Society that is fully international, and educational, and of a scien-tific organisation fostering excellence in the core disciplines of pharmacoeconomics and out-comes research. The conference provides a forum for learning and sharing important informa-tion through the short courses, as well as the main programme consisting of plenary sessions, issue panels, workshops, podium and poster presentations, which commences on Friday. There are many topics for consideration including the implementation of pharmacoeconomic guide-lines in evidence-based decision making in countries such as Argentina, Brazil, Chile, Colombia, Cuba, Guatemala, Mexico, Venezuela and Uruguay, in addition to issues of equity of access to health care in countries such as Argentina, Brazil, Colombia and Mexico.

The total number of ISPOR members including ISPOR chapter members now exceeds 7000 peo-ple worldwide. This conference and other ISPOR events such as the recent ISPOR 14th Annual International Meeting in Orlando, Florida, USA and the upcoming ISPOR 12th Annual European Congress in Paris, France are important venues for ISPOR as a society and for its members. Such meetings provide the opportunity for us as health care providers, policy makers, research-ers and students to meet, discuss and learn about areas of interest to us and our society.

I have little doubt that you will take advantage of the opportunity that the ISPOR 2nd Latin America Conference offers to share experiences and interact with your colleagues from around the world. Such activities will enable us to foster the ISPOR mission of promoting the science of pharmacoeconomics and outcomes research and facilitating the translation of this research into useful information for health care decision-makers to ensure that society allocates scarce health care resources wisely, fairly and efficiently.

Thank you for participating in the ISPOR 2nd Latin America Conference here in Rio de Janeiro. I do hope that you will enjoy the conference and the opportunity to network with colleagues and friends.

With best wishes,

Michael Barry PhD, MD, 2009 – 2010 ISPOR President & Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital & Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland

38

3100 Princeton Pike Building 3, Suite E Lawrenceville, NJ 08648 USAToll Free US and Canada: 1-800-992-0643 Tel: +1 609-219-0773 Fax: +1 609-219-0774Email: [email protected] Internet: www.ispor.org

2009-2010 Board of directorsPresident michael Barry Phd, md National Centre for Pharmacoeconomics St. James’s Hospital Dublin, Ireland [email protected]

President-elect Scott ramsey md, Phd Fred Hutchinson Cancer Research Center University of Washington Seattle, WA, USA [email protected]

Past President chris l. Pashos Phd HERQuLES, Abt Bio-Pharma Solutions, Inc. Lexington, MA, USA [email protected]

directors ansgar hebborn Phd F. Hoffmann-La Roche Basel, Switzerland [email protected]

Shanlian hu md, mSc Fudan University, School of Public Health Shanghai, P.R. China [email protected]

don husereau mSc Canadian Agency for Drugs & Technologies Ottawa, ON, Canada [email protected]

Zeba Khan rPh, Phd Celgene Corporation Summit, NJ, USA [email protected]

Paul Kind Centre for Health Economics University of York Heslington, York, UK [email protected]

Penny mohr ma Center for Medical Technology Policy Baltimore, MD, USA [email protected]

Shelby reed Phd, rPh Duke Clinical Research Institute Duke University Durham, NC, USA [email protected]

treasurer Karen rascati rPh, Phd University of Texas, College of Pharmacy Austin, TX, USA [email protected]

founding executive director marilyn dix Smith rPh, Phd ISPOR Lawrenceville, NJ, USA [email protected]

ISPORUniting Research & Practice

International Society for Pharmacoeconomics and outcomes research

Dear Colleagues,

We are pleased to welcome you to the ISPOR 2nd Latin America Conference in Rio de Janeiro, Brazil! As active promoters of pharmacoeconomics within Latin America, we are honored to be able to bring together researchers, academicians, government and industry representatives to discuss the use of this science in our region’s local health care decision making. The ISPOR staff, volunteer research reviewers, and this Committee have worked very hard to provide an exciting and stimulating program for you and your colleagues.

The theme of this Conference is “Uniting Research and Policy to Improve Health Care in Latin America”, and we hope you will take advantage of the breadth of information available through the Plenary Sessions, Short Courses, Workshops, and Poster Presentations – and, new this year, Issue Panels and Podium Presentations – presented at this Conference.

Our plenary sessions are designed to challenge and stimulate us to make pharmacoeconomics and outcomes research ever more relevant and useful to local decision-makers. The opening plenary session will address issues in the development and implementation of pharmacoeco-nomic guidelines. The second plenary will address equity of access to drugs in four countries in Latin America: Argentina, Brazil, Colombia and Mexico, and debate potential initiatives to address this issue.

We hope you will also take time to visit the many interesting and thought-provoking pre-sentations throughout the conference. Research was submitted from more than 25 different countries in 3 languages, and we think you will find their presentations quite interesting.

Thank you for coming and being a part of this wonderful organization. Enjoy the Conference!

Best regards,

Marcos Bosi Ferraz MD, PhDISPOR 2nd Latin America Conference Co-Chair Professor and DirectorSão Paulo Center for Health EconomicsFederal University of São PauloSão Paulo, Brazil

Gabriela Tannus Araújo MSc, MBAISPOR 2nd Latin America Conference Co-Chair Health Economics DirectorAxiaBio Consulting &Federal University of São Paulo Economist in Charge of the Clinical Trials Office UNIFESP/ SPDM, São Paulo, Brazil

39


cOnfeRence PROgRam cOmmIttee

CONFERENCE CO-CHAIRSMarcos Bosi Ferraz MD, PhD, Professor and Director, São Paulo Center for Health Economics, Federal University of São Paulo, São Paulo, Brazil

Gabriela Tannus Araújo MSc, MBA, Health Economics Director, AxiaBio Consulting, & Economist in Charge of the Clinical Trials Office, UNIFESP/ SPDM, São Paulo, Brazil

SHORT COURSE PROGRAM CO-CHAIRS Federico Augustovski MD, MSc, Director, Health Economic Evaluation and Technology Assessment, IECS (Institute for Clinical Effectiveness and Health Policy) & Staff Physician, Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Marino J. González R. PhD, MSc, MD, Professor of Public Policy and Health Policy, Unit of Public Policy, Simon Bolivar University, Caracas, Venezuela

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRSStephen Stefani MD, Medical Auditor, Head of Oncology Unit & Professor, UNIMED, Porto Alegre, Brazil

Walter R. Toro MD, PhD, Institutional Sales and Market Access Manager, Bayer Schering Pharma, Bogotá, Colombia

WORKSHOP REVIEW COMMITTEE CO-CHAIRSYajaira Bastardo PhD, Professor, School of Pharmacy, Central University of Venezuela, Caracas, Venezuela

Antonio Caso MD, MEd, Post Graduate Professor and Distance Learning Coordinator, Post Graduate Division, Faculty of Medicine, National University of Mexico, Mexico D.F, Mexico

RESEARCH REVIEW COMMITTEE CO-CHAIRSDiana Pinto MD, MHA, DSc, Associate Professor, Depart-ment of Clinical Epidemiology and Biostatistics, School of Medicine, Javeriana University & Research Associate, Fedesarrollo, Bogotá, Colombia

Emilio Santelices Cuevas MD, MBA, Medical Manage-ment Director, Clínica las Condes, Santiago, Chile

HEALTH CARE DECISION-MAKER CASE STUDY REVIEW COMMITTEE CHAIR

Mario Giorgio Saggia MBA, Health Economics Manager, Roche Brazil, São Paulo, Brazil

CONFERENCE OBJECTIVESParticipants will be able to:• Learnnewpharmacoeconomicmethodologiesandoutcomesresearchtechniques;• Improvethequalityoftheirdecisionmakingbybetterutilizationofpharmacoeconomic studies; and• Learnthelatestaboutmeasuringqualityoflifeandselectingappropriatesurvey instruments.

LANGUAGESOfficial Conference languages are English, Portuguese & Spanish. Plenary Sessions will be presented in English with simultaneous translation to Por-tuguese and Spanish. Other session languages are indicated alongside the session title in the Program & Schedule of Events.

GUIDE TO THE PROGRAM & SCHEDULE OF EVENTSFor your convenience, this Program & Schedule of Events has been printed in Portuguese, Spanish and English. For the Portuguese version, refer to pages 5-20. For the Spanish version, refer to pages 21-36. For the English version, refer to pages 37-52.

Issue Panels, Workshops and Symposia descriptions are included in all three languages, beginning on page 54.

Research Podium and Poster abstracts are included as submitted by authors. See page 95 for abstracts.

RESEARCH PODIUM & POSTER PRESENTATION ABSTRACTS Abstracts for all podium and poster research presentations given at the ISPOR 2nd Latin America Conference will be published in value in health

KeY InfORmatIOn

40


KeY InfORmatIOn

Volume 12, Issue 7. value in health Volume 12, Issue 7 will be available to ISPOR members and ISPOR 2nd Latin America Conference registrants on-line at: http://www.ispor.org/valueinhealth_index.asp in October 2009.

Research podium and poster abstracts are also included in this Program & Schedule of Events. See page 84 for Podium & Poster listings. Page num-bers to the left of the presentation code refer to the corresponding page of the podium/poster abstract in this Program & Schedule of Events.

FINANCIAL DISCLOSURE INFORMATION Research podium & poster presentation financial disclosure information will be available online after the Conference in October 2009 at: http://www.ispor.org/valueinhealth_index.asp and in value in health Volume 12, Issue 7.

ABSTRACT SUBMISSION HISTORICAL INFORMATION:

During the ISPOR 2nd Latin America Conference, 189 research posters, 45 research podiums, 8 workshops and 4 issue panels will be presented.

SPEAKER INFORMATIONAll speakers are requested to arrive at their presentation room 15 minutes prior to the session start time with their presentation on a USB/Flash Drive and required handouts (for podium, workshop and issue panel presenta-tions). ISPOR staff will assist the presenter with loading their presentation. Please note that all presentations submitted to ISPOR by the specified advance deadline will be pre-loaded onto the computer in the session room.

HANDOUTS • PlenarySessionsHandouts for the plenary session are available in the session room at the time of the presentations.• ResearchPresentations,Workshops&IssuePanelsHandouts for research (podium and poster) presentations, workshops and issue panels are the sole responsibility of the presenting author(s). ISPOR requires all contributed presenters to provide at least 200 copies of their handouts.• AllRemaining&AdditionalHandoutsAll remaining or additional handouts will be made available at the handout table near the ISPOR Registration Desk.

PLEASE NOTE: Following the conference, subject to author’s permission, released research presentations are available in the ISPOR Research Digest; a searchable database of over 10,000 research papers presented at ISPOR’s meetings from 1998 to date available at www.ispor.org.

RESEARCH POSTER PRESENTATIONS Poster presentations will be on view in Gávea B. Poster Display Hours: Friday, 11 September: 9:00-20:30Saturday, 12 September: 8:00-13:30

Poster Set-Up:Friday, 11 September: 8:00-9:00Poster Author Discussion Hour: Friday, 11 September: 18:30-19:30Poster Dismantle: Saturday, 12 September: 13:30-14:00

Poster presentations are organized using the following codes:(PCASE) - HEALTH CARE DECISION-MAKER’S CASE STUDIES(PCN) - CANCER(PCV) - CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)(PDB) - DIABETES/ENDOCRINE DISORDERS(PGI) - GI DISORDERS (PHC) - HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)(PHP) - HEALTH CARE USE & POLICY STUDIES(PIH) - INDIVIDUAL’S HEALTH (Children’s, Elderly’s, Men’s, Women’s)(PIN) - INFECTION(PMC) - METHODS & CONCEPTS(PMH) - MENTAL HEALTH(PMS) - MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)(PND) - NEUROLOGICAL DISORDERS(PRS) - RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)(PSS) - SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)(PSY) - SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)(PUK) - URINARY/KIDNEY DISORDERS

Presenters are required to be present at their posters during the Poster Author Discussion Hour. See page 84 for research poster presentation titles and authors and pages 95-130 for research poster abstracts. RESEARCH PRESENTATION AWARDS

Awards are given for the Best Podium and Poster Research Presentations (up to 6 in each category). All podium research presentations are considered for an award. Poster research presentations in the top 20%, based on abstract review score, are considered for a poster research presentation award. These are identified with a rosette.

The ISPOR Research Presentation Awards will be announced Saturday, 12 September at 13:00-13:30 in Gávea A.

EXHIBITS Exhibits will be on view in the Gávea Foyer:Friday, 11 September 2009: 9:00-20:30Saturday, 12 September 2009: 8:00-14:00

CONFERENCE PROGRAM WARNING Please be advised that recording, by any means, of conference presenta-tions is prohibited. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without the express approval from ISPOR.

Year Research Workshop Issue Case Total Not Panel Studies Accepted (%)

2007 117 12 - - 129 7.8%2009 256 8 5 8 277 7.2%

41


cOnfeRence at-a-gLance

THURSDAY, 10 SEPTEMBER

9:00-18:00 PRE-CONFERENCE SHORT COURSES

18:15-19:15 EDUCATIONAL SYMPOSIUM

19:30-20:30 SPECIAL SESSION PRESENTED BY THE ISPOR BRAZIL CHAPTER

20:30-22:30 WELCOME RECEPTION

FRIDAY, 11 SEPTEMBER

9:00-9:30 WELCOME ADDRESS & OPENING REMARKS

9:30-11:30 FIRST PLENARY SESSION

11:30-12:00 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING

12:00-13:00 RESEARCH PODIUM PRESENTATIONS – SESSION I

13:00-15:00 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING


15:00-16:00 ISSUE PANELS


16:15-17:15 WORKSHOPS – SESSION I

17:30-18:30 RESEARCH PODIUM PRESENTATIONS – SESSION II

18:30-19:30 RESEARCH POSTER AUTHOR DISCUSSION HOUR

18:30-20:30 RESEARCH POSTER PRESENTATIONS & EXHIBITOR’S RECEPTION


SATURDAY, 12 SEPTEMBER


8:00-9:00 EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING

9:00-10:30 SECOND PLENARY SESSION


10:45-11:45 RESEARCH PODIUM PRESENTATIONS – SESSION III

12:00-13:00 WORKSHOPS – SESSION II

13:00-13:30 ISPOR RESEARCH PRESENTATION AWARDS & CLOSING REMARKS

13:30-14:00 SYMPOSIUM RECEPTION


REGISTRATION 8:00-18:00

REG

ISTR

ATIO

N 8

:00-

18:0

0

EXH

IBIT

S &

PO

STER

PRE

SEN

TATI

ON

S 9

:00-

20:3

0

REG

ISTR

ATIO

N 7

:00-

13:3

0

EXH

IBIT

S 8:

00-1

4:00

42

POST

ER P

RESE

NTA

TIO

NS

8:00

-13:

30


ShORt cOuRSe PROgRam

THURSDAY, 10 SEPTEMBER MORNINGSHORTCOURSES(9:00-13:00)IntROductIOn tO mOdeLIng methOdS(Presented in spanish) Vidigal AFaculty: Jorge Guzmán MD, Access Manager, Novartis Oncology - Mexico, Colonia San Diego Churubisco, Mexico

Course Description: This course includes a review of Markov models, discrete event models, and other modeling techniques and their appro-priate applications, including a review of the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations. Using a series of related examples, the course will carefully review the practical steps involved in developing and using these kinds of models. Examples will be presented using predominantly Microsoft Excel, supplemented with add on simulation software. This course will cover the practical steps involved in the selec-tion and modeling of data inputs and practical aspects related to the determination of when, why and how to handle stochastic (i.e., first order Monte Carlo Simulations) and probabilistic uncertainty (i.e., second order Monte Carlo Simulations). Issues related to the selection of model input parameters and their distributions for use in probabilistic sensitivity analyses will be considered. Participants will learn the steps required in conducting, analyzing, interpreting, and presenting results from probabilistic sensitivity analyses (e.g. using analyses of the cost-effectiveness plane, the “ellipses”, and acceptability curves). this introductory course requires a familiarity with decision analysis.

PhaRmacOecOnOmIcS (ecOnOmIc eVaLuatIOnS) fOR decISIOn-maKeRS (Presented in spanish with simultaneous Portuguese translation) Gávea AFaculty: Adolfo Rubinstein MD, MSc, PhD, President, Institute for Clinical Effectiveness and Health Policy (IECS) & Director of the Master´s Program in Clinical Effectiveness, Faculty of Medicine, Uni-versity of Buenos Aires, Buenos Aires, Argentina

Course Description: This course is designed to teach clinicians and new researchers how to incorporate pharmacoeconomics into study design and data analysis. Participants will learn how to collect and calculate the costs of different health care or health care economic evaluation al-ternative treatments, determine the economic impact of clinical outcomes, and how to identify, track and assign costs to different types of health care resources used. The development of economic protocols and data collection sheets will be discussed. Different pharmacoeconomic models and techniques will be demonstrated as well as case studies. These include cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and cost-utility analysis. Decision analysis, sensitivity analysis, and discounting, will all be demonstrated and practiced. Participants will also learn to compare and evaluate interventions such as drugs, devices and clinical services. this course is suitable for those with little or no experience with pharmacoeconomics.

heaLth caRe & ReImbuRSement SYStemS In LatIn ameRIca (Presented in Portuguese) Gávea BFaculty: Fernanda O. Machado BDS, MSc, Medical & Health Eco-nomics Senior Manager, Johnson & Johnson Medical Brasil, São Paulo, Brazil

Course Description: Many countries in Latin America have only recently begun formulating the use of pharmacoeconomics and health outcomes research in medical decision making at an official level.

They are grappling with questions from payers and decision-makers on outcomes research and its use while still educating the general decision-making public on pharmacoeconomics and health outcomes research. This is particularly important for developing countries, where there is even more resource scarcity to be used in health technology assessment as well as a short supply of data on cost and effectiveness. The Latin American context requires special attention in (i) technical issues such as the election of the appropriate discount rate or the time horizon, (ii) a series of practical questions such as: should evidence be requested for all new drugs?, or just some?; how should drugs be prioritized for evaluation?; should data from other countries be accepted and, if so, which?; what are the major institutional constraints in the context of Latin American countries? This session will first discuss the cur-rent health care systems in the main Latin American countries, discussing research implementation and its linkage with regional priorities. The faculty will then describe the reimbursement legislation, processes and organizations within these countries as well as the role of the pharmaceutical and/or medical device manufacturer. This course will then focus on providing participants with an understanding of the vari-ous procedures employed by Latin American health authorities to regulate market access based upon the appraisal of the clinical and in some countries economic value of new medical technologies. Formulary submission guidelines set analytical and evidentiary standards which drug manufacturers and others are required to meet in making a case for their product. Faculty will discuss evidentiary standards in formu-lary submissions. this is an introductory level course.

eXtRactIng cOSt data fOR ecOnOmIc anaLYSIS In LatIn ameRIca (Presented in spanish) Vidigal BFaculty: Ximena Burbano MD, Research Director, Fundación Santa Fe de Bogotá – HEORT, Boca Raton, FL, USA & Bogotá, Colombia; Nelson Alvis Guzmán MD, MSc, PhD, Faculty of the Economic Sciences Department and Director of the Health Economics Research Group, Carta-gena University, Cartagena, Colombia; Heidy Cáceres MD, MSc, Outcomes Research Manager, Pfizer Colombia, Bogotá, Colombia

Course Description: This course will focus on practical aspects of cost development for pharmacoeconomic studies. The objective is to help the participant bridge the gap between understanding pharmacoeconomic theory and the practice of develop-ing cost estimates. Factors to consider when costing pharmacoeconomic analyses, such as perspective, data sources, data classification systems, developing resource use profiles, obtaining unit costs, and making cost adjustments will be presented. Examples of issues encountered when identifying and extracting cost data will be discussed. this course is designed for those with some experience with pharmacoeco-nomic analysis.

Morning Short Course Coffee Breakcoffee sponsored by ZRx outcomes Research

Short courses will be presented in either Portuguese, Spanish or English. Some courses will have simultaneous translation and are indicated by . Please see course titles for information regarding short course language.

J. Guzmán

A. Rubinstein

F.O. Machado

H. CáceresN.A. GuzmánX. Burbano

43


THURSDAY, 10 SEPTEMBER AFTERNOON SHORT COURSES (14:00-18:00)aPPLIed mOdeLIng (Presented in spanish) Vidigal AFaculty: Federico Augustovski MD, MSc, Director, Health Economic Evaluation and Technology Assess-ment, IECS (Institute for Clinical Effectiveness and Health Policy) & Staff Physician, Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Andrés Pichon-Riviere MD, MSc, PhD, Executive Director, IECS, Buenos Aires, Ar-gentina; Sebastián García Martí MD, Health Technol-ogy Assessment & Economic Evaluation, IECS, Buenos Aires, Argentina; Lisandro Colantonio MD, Research Fellow, IECS, Buenos Aires, Argentina

Course Description: This course is a hands-on intro-duction to the use of software in the creation and analysis of cost-effectiveness decision models. The basics of cost-effectiveness deci-sion making, building and analyzing a simple decision tree will be discussed. Markov modeling and Monte Carlo simulation will be introduced. All participants must bring a laptop computer with a copy of TreeAge Pro Suite installed and running. You will be provided download and installation instructions when you pre-register for the course. All participants will receive a CD-Rom at the training. this course is suitable for those who are familiar with the various modeling methods or who have taken the morning course, ‘introduction to modeling’.

heaLth technOLOgY aSSeSSment (Presented in Portuguese) Gávea BFaculty: Carisi Anne Polanczyk MD, PhD, Cardiology Service, Clinical Hospital of Porto Alegre – UFRGS & Associate Professor of Medicine, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil

Course Description: Health technology assessment (HTA) is the systematic evaluation of properties, effects and/or impacts of health care technology. Throughout the process of introducing a new technology, evaluating its effectiveness, approving its addition to the market and related decision making, important ethical, clinical and economic issues need to be addressed. This course will discuss current processes used globally to introduce a new technology and the agencies that perform these processes. It will include a review of the various meth-ods used to evaluate safety, efficacy, and technology adoption and diffusion, with emphasis on how to conduct HTA using real-world evidence. Faculty will address some of the issues facing current HTA processes such as their impact on the social and economic environment, the need for best practices, and the need for better co-operation among stakeholders. this course is designed for those with some experience in pharmacoeconomics.

utILItY meaSuReS (Presented in spanish) Vidigal BFaculty: Rafael Alfonso MD, MSc, Scientific Director, RANDOM Foundation, Bogotá, Colombia and PhD Student, University of Wash-ington, Seattle, WA, USA

Course Description: Utility measurement is a method of determin-ing an individual’s preference for a certain outcome represented by a quantitative score (utility). During this course, methods for measur-ing preference-based outcomes like the standard gamble, time trade-off, and visual analogue scale will be demonstrated. Additionally, utility-based instruments (EQ-5D, HUI, QWQ, SF-36) will be briefly discussed. Utility measurement however is not

only about mastering these techniques; it is about using them in such a way that health care decision-makers can apply the results, for instance in cost per QALY-analyses. For this purpose, one needs to be aware of shortcomings of the available utility measures and potential solutions. Furthermore, one should be aware of the decision-making context and the way results are interpreted. To equip participants with expertise in the field of utility measurement, the most important issues will be discussed: for instance we will consider potential insensitivity of generic instruments for particular disease-specific problems, and discuss to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution. Also the issue of “whose values count: patient values or values from the general public?” will be discussed. Finally we turn to the interpretation in the context of resource alloca-tion. this course is for those with some experience with quality of life measures in health economic evaluation.

tRanSfeRabILItY Of cOSt-effectIVeneSS data betWeen cOuntRIeS (Presented in english with simultaneous Portuguese and spanish translation) Gávea AFaculty: Michael Drummond MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Federico Augustovski MD, MSc, Director, Health Economic Evaluation and Technology Assessment, IECS (Institute for Clinical Effectiveness and Health Policy) & Staff Physician, Family and Community Medicine Division, Hos-pital Italiano de Buenos Aires, Buenos Aires, Argentina; David Thompson PhD, Vice President, Global Health Economics, i3 Innovus, Medford, MA, USA

Course Description: Although the number of countries requiring an economic dossier as part of the submission dossier for public reimbursement of new drugs is growing, the pharmaceutical industry cannot conduct economic evaluations in every potential market. Clinical trials are increasingly done in international settings in order to quickly recruit a sufficient number of patients and to have at least some economic data from multiple countries. However, national decision-makers require country-specific or region-specific data on health care costs and are only willing to accept foreign data or international data when they are translated to their own specific setting. However, little guidance on how to do this exists. This course starts with a discussion of factors that make economic data more difficult to transfer from one country to other countries than clinical data, and the evidence on the variability of cost-effectiveness results across countries. Then we will review the methods that have been presented to offer a solution to this problem and their pros and cons. Finally, we will discuss the emerging international guidance for dealing with issues of transferability, including the suggestions made by the ISPOR Good Practices Task Force on this topic. The methods to be discussed include various types of regres-sion based approaches and Markov models. An interactive exercise will be included and there will be discussion of the specific needs of the Latin American region. this course is for those with basic understanding of cost calculation and modeling.

Afternoon Short Course Coffee Breakcoffee sponsored by clinical therapeutics

ShORt cOuRSe PROgRam

A. Pichon-RiviereF. Augustovski

L. ColantonioS.G. Martí

C.A. Polanczyk

R. Alfonso

D. ThompsonF. AugustovskiM. Drummond

44


PROgRam & ScheduLe Of eVentS

THURSDAY,10SEPTEMBER2009

9:00-18:00 ShORt cOuRSeS (See page 43 for short course descriptions)

18:15-19:15 educatIOnaL SYmPOSIum (sPonsoRed By PFiZeR) Gávea A MODELSFORREIMBURSMENTFORONCOLOGYPRODUCTSINLATINAMERICANCOUNTRIES:THEPERSPECTIVEOF

BRAZIL,COLOMBIAANDMEXICO(Presented in simultaneous translation) (See page 65 for symposia descriptions)

19:30-20:30 SPecIaL SeSSIOn (Presented in Portuguese) Gávea A ADVANCESINTHEPROCESSOFHEALTHTECHNOLOGYASSESSMENTINBRAZIL:THEBRAZILIANNETWORKOFTECHNOLOGY

ASSESSMENT (REBRATS) Moderators: Gabriela Tannus Araújo MSc, MBA, ISPOR Brazil Chapter Director & Health Economics Director, AxiaBio Consulting, & Economist in Charge of the

Clinical Trials Office, UNIFESP/ SPDM, São Paulo, Brazil; Wilson Follador PhD, PharmD, MSc, Manager, Market Access and Health Economics, Sanofi-Aventis Farmaceutica Brazil & Director, ISPOR Brazil Chapter, São Paulo, Brazil

Panelists: Carisi Polanczyk MD, PhD, Cardiology Service, Clinical Hospital of Porto Alegre – UFRGS & Associate Professor of Medicine, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil; Flávia Elias MSc, Coordinator, DECIT/SCTIE/MS (Department of Science & Technology, Brazilian Ministry of Health), Brasilia, Brazil; Álvaro Atallah, MD, PhD, Director, Cochrane Center of Brazil / UNIFESP (Federal University of São Paulo), São Paulo, Brazil

20:30-22:30 ISPOR WeLcOme RecePtIOn Poolside All attendees welcome. co-sponsored by abbott laboratories

FRIDAY,11SEPTEMBER2009

9:00-9:30 WeLcOme & OPenIng RemaRKS (Presented in English with simultaneous Spanish & Portuguese translation) Gávea A (See page 70 for speaker biographical information) Marcos Bosi Ferraz MD, PhD, ISPOR Conference Co-Chair & Professor and Director, São Paulo Center for Health Economics, Federal

University of São Paulo, São Paulo, Brazil

Michael Barry MD, PhD, 2009-2010 ISPOR President & Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital & Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland

9:30-11:30 fIRSt PLenaRY SeSSIOn (Presented in English with simultaneous Spanish & Portuguese translation) Gávea A (See page 70 for biographical information) IMPLEMENTINGPHARMACOECONOMICGUIDELINESINEVIDENCE-BASEDDECISIONMAKINGINLATINAMERICA:LESSONSLEARNED? Pharmacoeconomic / economic (PE) evaluation is an analytical tool used to assist decision making in the financing

and management of pharmaceutical products in the health care system or national health insurance programs of an individual country. Pharmacoeconomic guidelines are a set of requirements for designing, conducting and reporting of PE studies. The development of PE guidelines by a health care system or health insurance program is usually the first step in the use of PE evaluations in health care / drug reimbursement decisions. The inclusion of PE evaluations in health care decisions in Latin America is changing; however, each country is undergoing this change at a different rate. During this plenary session, the development and implementation of PE guidelines including issues and barriers will be presented for three groups: countries currently implementing PE guidelines in drug reimbursement decisions; countries that are developing guidelines; and countries that are considering the development of PE guidelines.

9:30-9:40 Moderator: Michael Drummond MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

9:40-10:00 WHENTOCONSIDERTHEDEVELOPMENTOFPEGUIDELINES Lead Panelist: Federico Augustovski MD, MSc, Director, Health Economic Evaluation and Technology Assessment,

IECS (Institute for Clinical Effectiveness and Health Policy), Buenos Aires, Argentina

Panel Members: Gabriel Carrasquilla G. MD, MSc, DrPH, Director, Center for Health Care Research Studies (CEIS), Santa Fe de

Bogotá Foundation, Bogotá, Colombia

M. BarryM.B. Ferraz

G. CarrasquillaF. AugustovskiM. Drummond

M. GonzálezA. RodriguezP. de la Rosa

A. Lemgruber E. CuevasG. Melendez45


PROgRam and ScheduLe Of eVentS / fRIdaY, 11 SePtembeR Pamela de la Rosa PhD, Committee Leader for the Development of Pharmacoeconomic Guidelines, Medications Acces-

sibility Program, Ministry of Health, Guatemala, Guatemala Alarico Rodriguez de Léon MD, Medical Benefits Manager, Uruguayan National Agency for Highly Specialized Medical Procedures, Motevideo, Uruguay Marino J. González R. PhD, MSc, MD, Professor of Public Policy and Health Policy, Unit of Public Policy, Simon Bolivar University, Caracas, Venezuela

10:00-10:20 ISSUESTOCONSIDERINTHEDEVELOPMENTOFPEGUIDELINES Lead Panelist: Guillermo Melendez MD, MSc, Consultant, Mexican Health Foundation, Mexico City, Mexico

Panel Member: Emilio Santelices Cuevas MBA, MD, Director of Medical Management, Clinica las Condes, Providencia, Santiago, Chile

10:20-10:40 ISSUESTOCONSIDERINTHEIMPLEMENTATIONOFPEGUIDELINES Lead Panelist: Alexandre Lemgruber MSc, Head, Office of Economic Evaluation of New Technologies, Brazilian National Health Surveillance Agency (ANVISA),

Brasilia, Brazil Panel Member: Ana María Gálvez González PhD, MS, Economist, Professor & Chief, Department of Health Economics, National School of Public Health (ENSAP), Havana, Cuba

10:40-11:00 RESPONDENTDISCUSSION Respondents: David Bruhn PharmD, MBA, Outcomes Research Scientist, Lilly, San Diego, CA, USA

Joaquin Federico Mould Quevedo PhD, MBA, MSc, Outcomes Research Manager, Pfizer SA de CV, Mexico City, Mexico

11:00-11:30 PANELDISCUSSION&AUDIENCEQUESTIONS

11:30-12:00 bReaK, eXhIbIt & ReSeaRch POSteR PReSentatIOn VIeWIng Gávea B & Gávea Foyer (See page 84 for research poster presentations listing) coffee sponsored by i3 innovus

12:00-13:00 ReSeaRch POdIum PReSentatIOnS - SeSSIOn I (Page numbers shown to the left refer to the abstract location in this Program & Schedule of Events)

HEALTH CARE DECISION-MAKER’S CASE STUDIES (CASE1, CASE2 presented in Portuguese; CASE3 presented in Spanish) CopacabanaModerator: Adolfo Rubinstein MD, MSc, PhD, President, Institute for Clinical Effectiveness and Health Policy (IECS) & Director of the Master´s Program in Clinical Effectiveness, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina

pg131 CASE1 ANÁLISEDEAVALIAÇÕESECONÔMICASEMSAÚDENOPROCESSODEAVALIAÇÃODAINCORPORAÇÃODETECNOLOGIASDOMINISTÉRIODASAÚDEDOBRASIL

VieiraFS, Mendes ACR, Paes AC, Ministério da Saúde, Brasília, Distrito Federal, Brazil

pg131 CASE2 EXPERIÊNCIADOVILAVELHAHOSPITALPARAINCORPORAÇÃODENOVASTECNOLOGIASEMSAÚDENAPRESTAÇÃODESERVIÇOSDESAÚDESUPLE-MENTAR

Figueira CMG, Lanna PV, Vila Velha Hospital, Vila Velha, Espirito Santo, Brazil

pg131 CASE3 INSTRUMENTOSFINANCIEROSYVIABILIDADSECTORIAL Lazarov L, CINVE, Montevideo, Uruguay

COST STUDIES I (Presented in Spanish) LemeModerator: Federico Augustovski MD, MSc, Director, Health Economic Evaluation and Technology Assessment, IECS (Institute for Clinical Effectiveness and Health Policy) & Staff Physician, Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

pg132 CS1 COST-EFFECTIVENESSANALYSISOFACERVICALCANCERVACCINEINFIVELATINAMERICANCOUNTRIES Colantonio L1, Gomez J2, Demarteau N3, Standaert BA4, Pichon-Riviere A1, Augustovski FA1, Tatti SA5, Lorenzato F6, Carvalho NS7, Suarez E8, Shigematsu LMR9,

Salmeron J10, Bautista Garcia F11, Santos Ortiz C11, 1Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2GlaxoSmithKline Biologicals, Buenos Aires, Argentina, 3GlaxoSmithKline Biologicals, Wavre, Belgium, 4GlaxoSmithKline Biologicals, Rixensart, Belgium, 5Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina, 6GlaxoSmithKline Biologicals, Rio de Janeiro, Brazil, 7Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil, 8University of Chile, Santiago, Chile, 9National Institute of Public Health, Cuernavaca, Mexico, 10Instituto Mexicano de Seguro Social, Mexico DF, Mexico, 11National Institute of Neoplasic Diseases, Lima, Peru

pg132 CS2 COST-EFFECTIVENESSOFSMOKINGCESSATIONINTERVENTIONSINSEVENLATINAMERICANCOUNTRIES Pichon-Riviere A, Augustovski FA, Bardach A, Colantonio L, Rubinstein A, Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad Autónoma de Buenos Aires,

Argentina

pg132 CS3 UNMODELODECOSTO-UTILIDADDELTRASPLANTERENALENCOLOMBIA Rosselli D, Independiente, Bogotá, DC, Colombia

pg132 CS4 THECOSTANDHEALTHCONSEQUENCESOFSUBCUTANEOUSIMMUNOTHERAPYPLUSBECLOMETHASONEDIPROPIONATEINCOLOMBIANCHILDRENWITHMODERATEANDSEVEREASTHMA

Hernández L1, Castillo M2, García E3, 1United BioSource Corporation, Bogotá, Colombia; Universidad de Los Andes, Bogotá, Colombia, 2Universidad de Los Andes, Bogotá, Colombia, 3Fundación Santa Fe de Bogotá, Bogotá, Colombia

A. González J. QuevedoD. Bruhn

46


PROgRam and ScheduLe Of eVentS / fRIdaY, 11 SePtembeRRESEARCH ON METHODS I (MC1, MC2, MC3 presented in Spanish; MC4 presented in Portuguese) Vidigal ABModerator: Yajaria Bastardo PhD, Professor, School of Pharmacy, Central University of Venezuela, Caracas, Venezuela

pg133 MC1 VALORACIÓNSOCIALDELOSESTADOSDESALUDEQ-5DENCHILE:ALCANCESMETODOLÓGICOS ValenzuelaP1, Vignau A1, Olivares-Tirado P2, Muñoz A2, Kind P3, Zarate V3, 1Consultora DATAVOZ / STATCOM, Santiago, RM, Chile, 2Superintendencia de Salud,

Santiago, Chile, 3University of York, York, UK

pg133 MC2 SELF-PERCEPTIONOFHEALTHINLATINAMERICA Cabieses Valdes B1, Espinoza MA2, ZarateV3, 1Universidad del Desarrollo, Santiago, RM, Chile, 2Pontificia Universidad Catolica de Chile, Santiago, RM, Chile,

3University of York, York, UK

pg134 MC3 PREDICCIÓNDELRIESGOCARDIOVASCULARENPACIENTESDIABÉTICOSTIPO2UTILIZANDOÁRBOLESDEDECISIÓN:PRUEBADECONCEPTO Quiroz E1, Santelices E2, Lahsen R2, 1Universidad de Chile, Santiago, Santiago, Chile, 2Clínica Las Condes, Santiago, Santiago, Chile

pg134 MC4 COMPARISONOFDATAAVAILABILITYANDQUALITYFORPHARMACOECONOMICANALYSISINBRAZILVERSUSTHEUNITEDSTATESANDEUROPEANUNION:THECASESOFDIABETES&HYPERTENSION

Araujo G1, Campbell J2, Parekh HH2, Fonseca MCM3, Goncalves L4, Incze A5, Vincze G5, Thompson D2, 1Axia.Bio Consulting, São Paulo, Brazil, 2i3 Innovus, Medford, MA, USA, 3UNIFESP – Federal University of Sao Paulo, Sao Paulo, Brazil, 4Novartis Biociências S/A, São Paulo, Brazil, 5Novartis Pharma AG, Basel, Switzerland

PATIENT-REPORTED OUTCOMES STUDIES (Presented in English with simultaneous Portuguese and Spanish translation) Gávea AModerator: Lou Garrison PhD, Professor and Associate Director, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

pg132 PR1 LITERATUREREVIEWANDPRODUCTLABELCLAIMREVIEWOFPROMEASURESFORBENIGNPROSTATICHYPERPLASIA Angalakuditi M1, Pokrzywinski R2, Currie B3, Lenderking W3, 1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Pittsburgh, PA, USA,

3United BioSource Corporation, Bethesda, MD, USA

pg133 PR2 IMPROVEMENTINWORKPLACEANDHOUSEHOLDPRODUCTIVITYFORPATIENTSWITHEARLYRHEUMATOIDARTHRITISTREATEDWITHADALIMUMABPLUSMETHOTREXATE:WORKOUTCOMESANDTHEIRCORRELATIONSWITHCLINICALANDRADIOGRAPHICMEASURESFROMARANDOMIZEDCON-TROLLEDTRIALCOMPANIONSTUDY

vanVollenhovenR1, Cifaldi M2, Ray S2, Chen N2, Weisman MH3, 1Karolinska Institutet, Stockholm, Sweden, 2Abbott Laboratories, Abbott Park, IL, USA, 3Cedars Sinai Medical Center, Los Angeles, CA, USA

pg133 PR3 EFFECTOFPREHOSPITALIZATIONPERIODANDTYPEOFPESTICIDESONOUTCOMESINACUTEORGANOPHOSPHORUSPOISONING RoseXavierV1, Thunga G1, Sam KGS1, Kehra K2, 1Manipal University, Udupi, Karnataka, India, 2Manipal Acuova, Udupi, Karnataka, India

pg133 PR4 QUALITYOFLIFEINPATIENTSWITHEPIDERMOLYSISBULLOSA Tabolli S, Uras C, Paradisi A, Sampogna F, Di Pietro C, Abeni D, Zambruno G, IDI IRCCS, Rome, Italy

13:00-15:00 Lunch, eXhIbIt & ReSeaRch POSteR PReSentatIOn VIeWIng Gávea B & Gávea Foyer (See page 84 for research poster presentations listing)

13:30-14:30 educatIOnaL SYmPOSIum (sPonsoRed By ims) Gávea A USINGHEALTHECONOMICSANDOUTCOMESRESEARCHFORHEALTHCAREDECISIONMAKING–THECASEOF LATINAMERICA(Presented with simultaneous translation) (See page 66 for symposia descriptions)

15:00-16:00 ISSue PaneLS - SeSSIOn I (See page 54 for issue panel descriptions)

PATIENT-REPORTED OUTCOMES RESEARCH ISSUES

IP1:MEASURINGTHEBENEFITSOFHEALTHCARE:DALYSANDQALYS-DOESTHECHOICEOFMEASUREMATTER?(Presented in English) CopacabanaModerator: Federico Augustovski MD, MSc, Director Health Economic Evaluation and Technology Assessment, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, ArgentinaPanelists: PaulKind,Professor, Outcomes Research Group, University of York, York, UK; Joaquín Caporale MSc, Health Economist, Institute for Clinical Effectiveness and Health Policy (IECS) & National University of La Plata (UNLP), Buenos Aires, Argentina; Lisandro Colantonio, MD, MSc(c), Researcher, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP2:HEALTHTECHNOLOGYASSESSMENTANDPHARMACEUTICALPRICING:CAUSEORCONSEQUENCE?(Presented in English with simultaneous Spanish and Portuguese translation) Gávea AModerator: C. Daniel Mullins PhD, Professor and Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA Panelists: Alexandre Lemgruber MSc, HTA Manager, ANVISA, Brasilia, Góiás, Brazil; Rosa Rodriguez-Monguio PhD, Clinical Assistant Professor, School of Public Health, Ohio State University, Columbus, OH, USA; EnriqueSeoane-VazquezPhD,Assistant Professor, College of Pharmacy and College of Public Health, Ohio State University, Columbus, OH, USA

IP3:PAYFORPERFORMANCE:ISITPOSSIBLETOIMPROVETHEQUALITYOFHEALTHCAREWITHOUTMEDICALRENUMERATION?(Presented in Portuguese) Vidigal AB Moderator: Cesar LL Abicalaffe MD, MSc, Diretor Executivo, Impacto Tecnologias Gerenciais em Saude, Curitiba, Parana, BrazilPanelists: Paulo Borem MD, Director, UNIMED Belo Horizonte, Belo Horizonte, Brazil; Andrew Jones PHD, Professor Health Economics, University of York, York, UK; Maria Emi MD, Consultant MS, Impacto Tecnologias Gerenciais em Saude, Curitiba, Parana, Brasil

47


PROgRam and ScheduLe Of eVentS / fRIdaY, 11 SePtembeRIP4:FINANCINGOFHEALTHCARE:ISITPOSSIBLETORESTRICTNEWTECHNOLOGIESWITHOUTREDUCINGTHELEVELOFHEALTHOFAPOPULATIONANDWITHOUTSTOPPINGPROGRESS?(Presented in Portuguese) LemeModerator: Nelson Teich MD, President, MedInsight, Rio de Janeiro, BrazilPanelists: Denizar Araujo MD, Professor, Internal Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil; IsabelaSoaresSantosPhD,Head of Department, Health Technology Assessment, National Agency of Supplemental Health, Rio de Janeiro, Brazil; Cláudio Maierovitch Pessanha Henriques MD, Coordinator, CITEC (Commission for Incorporation of New Technologies), Secretariat of Science, Ministry of Health, Brasilia, Brazil

16:00-16:15 bReaK, eXhIbIt & ReSeaRch POSteR PReSentatIOn VIeWIng Gávea B & Gávea Foyer (See page 84 for research poster presentations listing)

16:15-17:15 WORKShOPS - SeSSIOn I (See page 58 for workshop descriptions)

CLINICAL OUTCOMES RESEARCH

W1:SEVERITYSCORINGCOMPARISIONOFMETHODS(Presented in English) LemeDiscussion Leaders:KarenL.RascatiPhD,Professor, College of Pharmacy, University of Texas at Austin, Austin, TX, USA; Bradley C. Martin PharmD, PhD, Professor, Pharma-ceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Lung-ICheng, Graduate Student, College of Pharmacy, University of Texas at Austin, Austin, TX, USA

ECONOMIC OUTCOMES RESEARCH

W2:THENEWGERMANMETHODSFORECONOMICEVALUATION:ARETHEYAPPLICABLEINLATINAMERICA (Presented in Spanish) Vidigal ABDiscussion Leaders: J. Jaime Caro MDCM, FRCPC, FAC, Adjunct Professor, McGill University, Montreal, QC, Canada & Senior Vice-President of Health Economics, United Bio-Source Corporation, Lexington, MA, USA; Charalabos-Markos Dintsios MA, MPH, Research Fellow, Pharmaceutical Products Evaluation, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH

W3:VALUINGHEALTHFORECONOMICEVALUATIONINLATINAMERICA:THECASEFORSTANDARDMETHODOLOGYBASEDONEQ-5D (Presented in English with simultaneous Portuguese and Spanish translation) Gávea ADiscussion Leaders: PaulKind,Professor, Outcomes Research Group, York, University of York, York, UK; Federico Augustovski MD, MSc, Director, Health Economic Evalua-tion and Technology Assessment, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; VictorZarateMD,MSc,PhD Student, Centre for Health Economics, University of York, York, UK; PaulinaValenzuelaMSc,Executive Director and Consultant, DATAVOZ / STATCOM, Santiago, Chile

USE OF REAL WORLD DATA

W4:WORKSHOPONTHEDESCRIPTION,RELIABILITYANDVALIDITYOFDATAPRESENTINTHEADMINISTRATIVEDATABASESOFQUEBEC(Presented in English) CopacabanaDiscussion Leaders: Sylvie Perreault PhD, Associate Professor, Pharmacy, University of Montreal, Montreal, QC, Canada; Yola Moride PhD, Associate Professor, Faculty of Phar-macy, University of Montreal, Montreal, QC, Canada; Anick Bérard PhD, Associate Professor, Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada; Elham Rahme PhD, Associate Professor, McGill University, Montreal, QC, Canada

17:30-18:30 ReSeaRch POdIum PReSentatIOnS - SeSSIOn II (Page numbers shown to the left refer to the abstract location in this Program & Schedule of Events)

COST STUDIES II (CS5, CS7 presented in Portuguese; CS6, CS8 presented in English) LemeModerator: Guillermo Salinas Escudero, MSc, Economic Researcher, Hosipal Infantil de Mexico (invited)

pg134 CS5 GASTOSELEVADOSCOMMEDICAMENTOSDOPROGRAMADEMEDICAMENTOSEXCEPCIONAISDOMINISTÉRIODASAÚDE/BRASIL Brandao CMR1, Acurcio FA1, Andrade IG1, Cherchiglia ML1, Silva GD2, Guerra Jr AA2, Almeida AM1, Queiroz OV1, SZuter DC1, Faleiros DR2, Jorge EA3, 1Universidade

Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 2Secretaria de Estado da Saúde de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 3Ministério da Saúde, Brazília, Distrito Federal, Brazil

pg134 CS6 THEINTRODUCTIONOFPRE-ENDOSCOPY(EGD)HIGH-DOSEINTRAVENOUSPROTONPUMPINHIBITION(HDIVPPI)INTHEMANAGEMENTOFPATIENTSWITHACUTEUPPERGASTROINTESTINALBLEEDING(UGIB)-ABUDGETIMPACTANALYSIS

Barkun A1, Teich V2, Gralnek IM3, Bardou M4, Adam V5, 1McGill University, Montreal, Quebec, Canada, 2MedInsight, Rio de Janeiro, Brazil, 3Rambam Health Care Campus, Haifa, Israel, 4University of Burgundy, Dijon, Bourgogne, France, 5McGill University Health Centre, Montreal, QC, Canada

pg134 CS7 COST-EFFECTIVENESSANDBUDGETIMPACTOFINTRODUCINGROSUVASTATININTOTHEBRAZILIANNATIONALDRUGFORMULARY Godoy MR1, Bueno RLP2, 1UFRGS - Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 2UFF - Fluminense Federal University, São

Paulo, Brazil

pg135 CS8 THEECONOMICBURDENOFGAUCHERANDFABRY’SDISEASEINCOLOMBIA.IMPLICATIONSFORNATIONALHEALTHINSURANCE Pinto DM1, Dennis R2, Parra O3, 1Fedesarrollo, Bogotá, Colombia, 2Pontificia Universidad Javeriana, Bogotá, Colombia, 3Politecnico Grancolombiano, Bogotá, Colombia

COST STUDIES III (Presented in Spanish) CopacabanaModerator: Diana Pinto MD, MHA, DSc, Associate Professor, Department of Clinical Epidemiology and Biostatistics, School of Medicine, Javeriana University & Research Associ-ate, Fedesarrollo, Bogotá, Colombia

pg135 CS9 ESTIMATIONOFTHEBURDENOFCARDIOVASCULARDISEASEATTRIBUTABLETOMODIFIABLERISKFACTORSANDCOST-EFFECTIVENESSANALYSISOFPREVENTIVEINTERVENTIONSTOREDUCETHISBURDENINARGENTINA

Rubinstein A1, Colantonio L1, Bardach A1, Caporale JE1, Garcia Marti S1, Gibbons L1, Kopitowski K2, Alcaraz A1, Augustovski FA1, Pichon-Riviere A1, 1Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2Servicio de Medicina Familiar y Comunitaria, Buenos Aires, Argentina48


PROgRam and ScheduLe Of eVentS / SatuRdaY, 12 SePtembeRpg135 CS10 ANÁLISISDECOSTOEFECTIVIDADYCOSTOUTILIDADDELINTERFERÓNBETA-1B(INF1B)FRENTEAINTERFERÓNBETA-1A(INF1A)PARAEL

TRATAMIENTODEESCLEROSISMÚLTIPLEREMITENTERECIDIVANTEENCOLOMBIA Romero M1, Arango CH1, Alvis N2, Canon O3, 1Synergia Consultoría y Gestión S.A, Bogotá D.C, Colombia, 2Universidad de Cartagena, Cartagena, Colombia,

3Fundación Salutia, Bogotá, Colombia

pg135 CS11 COST-EFFECTIVENESSOFSELECTIVESEROTONINREUPTAKEINHIBITORSINTHETREATMENTOFMAJORDEPRESSIONINMEXICO Idrovo J, Rivas R, Zapata L, Guia Mark, Mexico, DF, Mexico

pg135 CS12 IMPACTOEPIDEMIOLÓGICOYECONÓMICODELAINTRODUCCIÓNDELAVACUNADEHEPATITISAENCOLOMBIA de La Hoz F1, Alvis N2, Pérez B1, Narváez J1, Orozco J3, Alvis L2, 1Universidad Nacional de Colombia, Bogotá D.C, Colombia, 2Universidad de Cartagena, Cartagena,

Colombia, 3AYGES Consultoría S.A, Cartagena, Colombia

HEALTH CARE USE & POLICY STUDIES I (HP1, HP2, HP4 presented in Portuguese; HP3 presented in Spanish) Vidigal ABModerator: Sebastián García Martí MD, MSc, Health Technology Assessment & Economic Evaluation, IECS, Buenos Aires, Argentina (invited)

pg136 HP1 CONHECIMENTODAPOPULAÇÃOBRASILEIRADOCÂNCERDEMAMAESEUDIAGNÓSTICO Caleffi M1, Boscatti FHG2, Muranaka AH3, 1FEMAMA ( National Coalition of Non-Profit Organizations to Support Breast Cancer Care), Porto Alegre, RS, Brazil,

2Universidade de São Paulo, São Paulo, SP, Brazil, 3Universidade Federal de São Paulo, São Paulo, SP, Brazil

pg136 HP2 HEALTHTECHNOLOGYASSESSMENTINLATINAMERICAANDTHECARIBBEAN,FACILITATORSANDBARRIERSFORINTERNATIONALCOLLABORATION:ASURVEY

Pichon-Riviere A1, Ceballos RM2, Briones E3, 1Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad Autónoma de Buenos Aires, Argentina, 2CENETEC - Centro Nacional de Excelencia Tecnologica en Salud, Mexico DF, Mexico, 3Valme University Hospital, Seville, Spain

pg136 HP4 INFLUÊNCIADAAVALIAÇÃODETECNOLOGIASEMSAÚDENOSPROCESSOSDETOMADADEDECISÃONOSISTEMAÚNICODESAÚDE Laranjeira FO, Conti MA, Salomon FCR, Louly PG, Elias FTS, Ministry of Health of Brazil, Brasília, DF, Brazil

RESEARCH ON METHODS II (Presented in English with simultaneous Portuguese and Spanish translation) Gávea AModerator: J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President, Health Economics, United BioSource Corporation, Health Care Analytics, Lexington, MA, USA

pg136 MC5 TOWARDANECONOMICFRAMEWORKFORUNDERSTANDINGPERFORMANCE-BASEDRISK-SHARINGAGREEMENTSFORINNOVATIVEMEDICALPRODUCTS

Garrison LP1, Towse A2, 1University of Washington, Seattle, WA, USA, 2Office of Health Economics, London, UK

pg136 MC6 SCHIZOPHRENIAMODELING:MARKOVMODELWITHMONTE-CARLOMICROSIMULATION Dragomir A1, Tarride JE2, Joober R3, Angers JF1, Rouleau G1, Drapeau P1, Perreault S1, 1University of Montreal, Montréal, QC, Canada, 2McMaster University,

Hamilton, ON, Canada, 3McGill University, Montreal, QC, Canada

pg137 MC8 COMPARISONOFMETHODSFORIDENTIFYINGDEPRESSIONINPATIENTSWITHDIABETESUSINGPHYSIOLOGIC,SOCIAL,ANDDISEASESEVERITYMEASURES

Feeney P1, O’Connor PJ2, Raisch DW3, Sullivan MD4, 1Wake Forest University Health Sciences, Winston-Salem, NC, USA, 2HealthPartners Research Foundation, Bloomington, MN, USA, 3University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 4University of Washington, Seattle, WA, USA

18:30-19:30 ReSeaRch POSteR authOR dIScuSSIOn hOuR Gávea B (See page 84 for research poster presentations listing)

18:30-20:30 ReSeaRch POSteR PReSentatIOn VIeWIng & eXhIbItOR’S RecePtIOn Gávea B & Gávea Foyer (See page xx for research poster presentations listing)

19:30-20:30 educatIOnaL SYmPOSIum (sPonsoRed By lilly) Gávea A LEARNINGSANDAPPLICATIONTOHEALTHTECHNOLOGYASSESSMENTINLATINAMERICA–STRUCTURAL

COMPONENTS,OPERATIONALISSUES,ANDTECHNICALCONSIDERATIONS(Presented with simultaneous translation) (See page 67 for symposia descriptions)

SATURDAY,12SEPTEMBER2009

7:30-8:30 educatIOnaL SYmPOSIum (sPonsoRed By sanoFi PasteUR) Gávea A VALUEOFVACCINATION:TIMETOWAKEUP! (See page 68 for symposia descriptions)

8:00-9:00 eXhIbItS & ReSeaRch POSteR PReSentatIOnS VIeWIng Gávea B & Gávea Foyer

49


PROgRam and ScheduLe Of eVentS / SatuRdaY, 12 SePtembeR

9:00-10:30 SecOnd PLenaRY SeSSIOn (Presented in English with simultaneous Spanish & Portuguese translation) Gávea A (See page 70 for speaker biographical information) ISEQUITYOFACCESSTOHEALTHCAREINLATINAMERICAACHIEVABLE? Despite improvements in indicators of health over the past few decades, health care inequities, specifically access

to drugs, between and within countries in Latin America, have persisted. Most face issues of lack of coverage for a portion of the population or for a particular health state – or both. This plenary session will address equity of access to drugs in four countries in Latin America: Argentina, Brazil, Colombia and Mexico. A speaker from each country will briefly describe the current situation concerning inequity in access to drugs and then present pro-grams and/or solutions to these inequities, which are or could be implemented in their country. A respondent will challenge the presenters with specific issues to address when developing solutions to these inequities

Moderator: Gabriela Tannus Araújo MSc, MBA, ISPOR Conference Co-Chair & Health Economics Director, Axia.Bio Consulting & Economist in Charge of the Clinical Trials Office, UNIFESP/ SPDM, São Paulo, Brazil

Speakers: Joaquín E. Caporale MSc, Health Economist, Institute for Clinical Effectiveness and Health Policy (IECS) & Na-tional University of La Plata (UNLP), Buenos Aires, Argentina Antonio Caso MD, MEd, Post Graduate Professor and Distance Learning Coordinator, Post Graduate Division, Faculty of Medicine, National University of Mexico, Mexico D.F, Mexico Diana Pinto MD, MHA, DSc, Associate Professor, Department of Clinical Epidemiology and Biostatistics, School of Medicine, Javeriana University & Research Associate, Fedesarrollo, Bogotá, Colombia Stephen Stefani MD, Medical Auditor, Head of Oncology Unit & Professor, UNIMED, Porto Alegre, Brazil

Respondent: Lou Garrison PhD, Professor and Associate Director, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

10:30-10:45 bReaK, eXhIbIt & ReSeaRch POSteR PReSentatIOn VIeWIng Gávea B & Gávea Foyer (See page 84 for research poster presentations listing)

10:45-11:45 ReSeaRch POdIum PReSentatIOnS - SeSSIOn III (Page numbers shown to the left refer to the abstract location in this Program & Schedule of Events)

CLINICAL OUTCOMES STUDIES (CO1 presented in Portuguese; CO2 presented in Spanish; CO3, CO4 presented in English) LemeModerator: Rozana Mesquita Ciconelli MD PhD, Affiliate Professor, Federal University of Sao Paulo, Sao Paulo, Brazil (invited)

pg137 CO1 GANHOSASSOCIADOSAEXAMESCLÍNICOSASSOCIADOSAORASTREAMENTOMAMOGRÁFICOPARAMULHERESACIMADOS40ANOS Caleffi M1, Boscatti FHG2, Ribeiro RA1, Bedin Junior A1, Duarte Filho D1, Muranaka AH3, Weber B1, 1Hospital Moinhos de Vento, Porto Alegre, RS, Brazil,

2Universidade de São Paulo, São Paulo, SP, Brazil, 3Universidade Federal de São Paulo, São Paulo, SP, Brazil

pg137 CO2 PRESCRIPCIÓNDEMEDICAMENTOSPOTENCIALMENTEINAPROPIADOSENADULTOSMAYORESHOSPITALIZADOS Jirón M1, Escobar L1, Orellana S1, Jara P1, Oyarzún X1, Arriagada L2, Griñen H1, 1Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago,

Chile, 2Hospital Clínico de la Universidad de Chile, Santiago, Chile

pg137 CO3 HOWANDWHYAUTOMATEDMEDICALDATABASESSHOULDBEUSEDTOCREATEBACKGROUNDOCCURRENCESFORDRUGOUTCOMESANDSAFETYSTUDIES:GLAUCOMAINTHIN(UK)

Maguire A1, Blak BT2, 1United BioSource Corporation, London, UK, 2CSD EPIC, London, UK

pg137 CO4 AUTOMATEDPHONECALLSIMPROVEDADHERENCETOINHALEDCORTICOSTEROIDS Feldstein A1, Vollmer W2, Rand C3, 1Kaiser Permanente, Portland, OR, USA, 2Kaiser Permanente Northwest Center for Health Research, Portland, OR, USA, 3Johns

Hopkins University, Baltimore, MD, USA

COST STUDIES IV (Presented in English with simultaneous Portuguese and Spanish translation) Gávea AModerator: Rafael Alfonso MD, MSc, Scientific Director, RANDOM Foundation and PhD Student, University of Washington, Seattle, WA, USA & Bogota, Colombia

pg138 CS13 CLINICALEFFECTIVENESSANDCOSTUTILITYOFTRUVADA,KIVEXAANDCOMBIVIRINTHETREATMENTOFANTIRETROVIRALNAÏVEHIV-1INFECTEDPATIENTSINMEXICO

RelyK1, Pierre KA2, Salinas EG3, 1Network on the Economic Evaluation of Healthcare Programmes and its Applications to Decision Making in Latin American Countries, Mexico DF, Mexico, 2Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 3Hospital Infantil de México Federico Gómez, Mexico DF, Mexico

pg138 CS14 ASSESSMENTOFTHEECONOMICALIMPACTOFNON-PERSISTENCEWITHANTIDEPRESSANTTREATMENTSUSINGTHEADMINISTRATIVECLAIMSDATABASE OF QUEBEC (CANADA)

Beland SG1, Moride Y1, Pariente A2, Tournier M2, Lebeau M1, Galbaud du Fort G3, Crott R4, Ducruet T3, 1Université de Montreal, Montréal, QC, Canada, 2Victor Segalen Bordeaux 2, Bordeaux, France, 3McGill University, Montreal, QC, Canada, 4Université Catholique de Louvain, Brussels, Belgium

pg138 CS15 ECONOMICBURDENASSOCIATEDWITHDOSE-TITRATIONATINITIATIONTOMANAGEDCAREINPATIENTSWITHNON-PSYCHOTICMAJORDEPRES-SIVEDISORDER

Camacho F1, Joish VN2, Kong MC3, Sheehan D4, Balkrishnan R3, 1Penn State College of Medicine, Hershey, PA, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3The Ohio State University College of Pharmacy, Columbus, OH, USA, 4University of South Florida College of Medicine, Tampa, FL, USA

L. GarrisonS. StefaniD. Pinto

A. CasoJ. Caporale G. Araújo

50


PROgRam and ScheduLe Of eVentS / SatuRdaY, 12 SePtembeRpg138 CS16 COSTUTILITYOFPOSACONAZOLEVERSUSFLUCONAZOLE/ITRACONAZOLETHERAPYINTHEPROPHYLAXISAGAINSTINVASIVEFUNGALINFECTIONS

AMONGHIGH-RISKNEUTROPENICPATIENTSINMEXICO RelyK1, Pierre KA2, Salinas EG3, 1Network on the Economic Evaluation of Healthcare Programmes and its Applications to Decision Making in Latin American

Countries, Mexico DF, Mexico, 2Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 3Hospital Infantil de México Federico Gómez, Mexico DF, Mexico

COST STUDIES V (CS17 presented in Spanish; CS19 presented in Portuguese; CS18, CS20 presented in English) CopacabanaModerator: Ewaldo Russo PhD, MD, Member & Professor, Centro Paulista de Economia da Saude, Sao Paulo, Brazil

pg138 CS17 COSTOSDELAESCLEROSISMÚLTIPLEENCOLOMBIA Romero M1, Arango CH1, Alvis N2, Canon O3, 1Synergia Consultoría y Gestión S.A, Bogotá D.C, Colombia, 2Universidad de Cartagena, Cartagena, Colombia,

3FUNDACION SALUTIA, Bogotá, Colombia

pg139 CS18 ECONOMICEVALUATIONOFBARIATRICSURGERYASTREATMENTFOROBESITYANDASSOCIATEDCOMORBIDITIES.ESTIMATIONBYDISCRETEEVENTSIMULATION

Cabra HA1, Zanela OO1, Anaya P2, Rodriguez S1, 1Johnson & Johnson Medical Mexico, Mexico City, DF, Mexico, 2Fundación Mexicana para la Salud, Mexico City, DF, Mexico

pg139 CS19 AUDITORIABASEADAEMEVIDÊNCIAS(ABE):IMPACTONOCUSTODOTRATAMENTOQUIMIOTERÁPICOAPÓS3ANOSDEIMPLANTAÇÃO Clark LG, Alves AF, Castro AP, Santos FS, Clark O, Engel T, Paladini L, Pegoretti B, Faleiros E, Evidencias Medicas, Campinas, São Paulo, Brazil

pg139 CS20 RELATIONSHIPBETWEENADHERENCELEVELTOSTATINSANDCLINICALISSUESANDHEALTHCARECOSTSINREALLIFECLINICALSETTING Dragomir A1, Côté R2, Perreault S1, 1University of Montreal, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada

HEALTH CARE USE & POLICY STUDIES II (HP5 presented in English; HP6, HP7, HP8 presented in Spanish) Vidigal ABModerator: Emilio Santelices Cuevas MBA, MD, Director of Medical Management, Clínica las Condes, Providencia, Santiago, Chile

pg139 HP5 PROFILEOFHTAUSERSANDAPPLICABILITYOFHTAREPORTSTOINFORMDECISIONSINLATINAMERICA Pichon-Riviere A, Augustovski FA, Rubinstein A, Garcia Marti S, Calcagno JI, Liu NH, Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad Autónoma de

Buenos Aires, Argentina

pg139 HP6 EVALUACIÓNECONÓMICADELATERAPIACONESTATINASENPREVENCIÓNSECUNDARIA:REVISIÓNSISTEMÁTICADELALITERATURA González R MJ1, Valarino AI1, Rincón E1, Oropeza A1, Pinedo R2, Adesso G3, 1Universidad Simón Bolívar, Baruta, Caracas, Venezuela, 2University of York, York, UK,

3Universidad Central de Venezuela, Caracas, Venezuela

pg140 HP7 FACTORESPREDICTIVOSDELÉXITOENUNPROGRAMADECESACIÓNTABAQUICAENMÉXICO HerediaI1, Colchero A1, Sansores R2, Ramírez A2, 1Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico, 2Instituto Nacional de Enfermedades

Respiratorias, Mexico D.F., Mexico

pg140 HP8 REGULACIÓNYPATRONESDEPRÁCTICAACERCADETRATAMIENTOSORALESDELADIABETESTIPO2ENLATINOAMÉRICA Augustovski FA1, Garcia Elorrio E1, Acosta A2, Pichon-Riviere A1, Rubinstein A1, 1Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina,

2Universidad Nacional de Colombia, Bogotá, Colombia

12:00-13:00 WORKShOPS - SeSSIOn II (See pages 58 for workshop descriptions)

ECONOMIC OUTCOMES RESEARCH

W5:THECHALLENGESOFFUNDINGDIABETESCAREANDANSWERSFROMHEALTHECONOMICRESEARCH(Presented in English) CopacabanaDiscussion Leaders: KurtNeeserDVM,MPH,Head of Modeling and Health Economics, Department of Health Economics, Institute for Medical Informatics and Biostatistics, Basel, Switzerland; Oliver Mast MSc, Head of Global Reimbursement, Roche Diagnostics, Ltd, Mannheim, Germany

W6:WORKPRODUCTIVITYOFPATIENTSWITHRHEUMATOIDARTHRITIS(RA):DOTUMORNECROSISFACTORANTAGONISTSPLAYAROLE?(Presented in English) Vidigal ABDiscussion Leaders: Sanjoy Roy PhD, Manager, Abbott Laboratories, Abbott Park, IL, USA; Howard Birnbaum PhD, Principal, Analysis Group, Inc, Boston, MA, USA; Denizar ViannaMD,MSc,PhD,Associate Professor, Department of Internal Medicine, University of Rio de Janeiro, Rio de Janeiro, Brazil; Mary Cifaldi PhD, Director, Abbott Laboratories, Abbott Park, IL, USA

USE OF REAL WORLD DATA

W7:THEINCREASINGNEEDFORREALLIFEDATAFROMOBSERVATIONALSTUDIESTOACHIEVEREIMBURSEMENTANDMARKETACCESSOBJECTIVES (Presented in Spanish with simultaneous English and Portuguese translation) Gávea ADiscussion Leaders: Jonothan Tierce CPhil, General Manager and Center of Excellence Leader HEOR, Health Economics & Outcomes Research, IMS Health, Falls Church, VA, USA; Federico Augustovski MD, MSc, Director, Health Economic Evaluation and Technology Assessment, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Xavier Badia MD, PhD, Senior Principal HEOR, General Manager of Observational Outcomes Research Center of Excellence, Health Economics and Outcomes Research, IMS Health, Barcelona, Spain; GilbertL’italienPhD, Group Director, Epidemiology and Outcomes Research, Latin America & Canada, Epidemiology and Outcomes Research, Bristol Myers Squibb , Wallingford, CT, USA

W8: RISKADJUSTMENTMODELSINTHEEVAUATIONOFHEALTHSERVICES (Presented in Spanish) LemeDiscussion Leaders: Antonio Sarría Santamera MD, PhD, Investigador Titular, AETS-ISCIII, Universidad de Alcala, Madrid, Spain; Javier Trujillano MD, PhD, Profesor, Unidad de Cuidados Intensivos Hospital Arnau de Vilanova, Departamento de Ciencias Medicas Básicas, Universitat de Lleida, Lleida, Cataluña, Spain

51


PROgRam and ScheduLe Of eVentS / SatuRdaY, 12 SePtembeR13:00-13:30 ReSeaRch PReSentatIOn aWaRdS and cLOSIng RemaRKS Gávea A (Presented in English with simultaneous Spanish and Portuguese translation) Presenters: Gabriela Tannus Araújo MSc, MBA, ISPOR Conference Co-Chair & Health Economics Director, Axia.Bio Consulting & Economist in Charge of the Clinical Trials

Office, UNIFESP/ SPDM, São Paulo, Brazil

Marcos Bosi Ferraz MD, PhD, ISPOR Conference Co-Chair & Professor and Director, São Paulo Center for Health Economics, Federal University of São Paulo, São Paulo, Brazil

13:30-14:00 SYmPOSIum RecePtIOn (sPonsoRed By millcReeK oUtcomes gRoUP, llc) Gávea Foyer all symposium attendees welcome.

14:00-17:00 educatIOnaL SYmPOSIum (sPonsoRed By millcReeK oUtcomes gRoUP, llc) Gávea A REIMBURSEMENTREVIEWPROCESSACROSSLATINAMERICA(Presented with simultaneous translation) (See page 69 for symposia descriptions)

52

Mexican College for Pharmacoeconomics and … College for Pharmacoeconomics and Outcomes Research,...

Documents

Transcript of Mexican College for Pharmacoeconomics and … College for Pharmacoeconomics and Outcomes Research,...